Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.78 -4.8%	$6.20	$4.34 ▼ $12.38	$340.58M	0.45	228,659 shs	167,413 shs
ELUT Elutia	$2.11 +3.9%	$1.91	$1.61 ▼ $5.12	$86.76M	0.88	40,310 shs	2,322 shs
FULC Fulcrum Therapeutics	$7.67 -3.5%	$6.91	$2.32 ▼ $10.13	$413.76M	2.37	526,059 shs	247,692 shs
GLUE Monte Rosa Therapeutics	$5.89 -0.3%	$4.62	$3.50 ▼ $12.40	$361.99M	1.41	630,915 shs	339,876 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+2.45%	+5.17%	+15.21%	+32.84%	-22.78%
ELUT Elutia	0.00%	-17.14%	+14.69%	-12.50%	-49.75%
FULC Fulcrum Therapeutics	+0.76%	-0.87%	+23.48%	+141.34%	-5.02%
GLUE Monte Rosa Therapeutics	+5.17%	+12.17%	+29.10%	+29.67%	+24.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.5386 of 5 stars	3.6	1.0	3.0	3.3	0.0
ELUT Elutia	3.7159 of 5 stars	3.5	5.0	2.7	3.3	0.6
FULC Fulcrum Therapeutics	0.6128 of 5 stars	1.3	2.0	2.1	2.5	0.0
GLUE Monte Rosa Therapeutics	2.1226 of 5 stars	3.3	1.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	224.72% Upside
ELUT Elutia	3.00	Buy	$8.00	279.15% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-17.99% Downside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	160.55% Upside

Current Analyst Ratings Breakdown

Latest ELUT, FULC, AURA, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/9/2025	ELUT Elutia	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
ELUT Elutia	$24.38M	3.56	N/A	N/A	($1.31) per share	-1.61
FULC Fulcrum Therapeutics	$80M	5.17	N/A	N/A	$4.51 per share	1.70
GLUE Monte Rosa Therapeutics	$75.62M	4.79	N/A	N/A	$3.63 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
ELUT Elutia	-$53.95M	-$1.93	N/A	N/A	N/A	-168.23%	N/A	-96.70%	7/28/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	73.57	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)

Latest ELUT, FULC, AURA, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	N/A	N/A	N/A	$7.23 million	N/A
7/30/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/8/2025	Q1 2025	ELUT Elutia	-$0.20	-$0.21	-$0.01	-$0.21	$6.65 million	$6.03 million
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
ELUT Elutia	N/A	0.81	0.70
FULC Fulcrum Therapeutics	N/A	28.71	28.71
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
ELUT Elutia	74.03%
FULC Fulcrum Therapeutics	89.83%
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
ELUT Elutia	27.60%
FULC Fulcrum Therapeutics	7.00%
GLUE Monte Rosa Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable

ELUT, FULC, AURA, and GLUE Headlines

Recent News About These Companies

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.3% - Should You Buy?

July 17 at 4:13 AM | marketbeat.com

Molecular glue degraders are more versatile than previously thought

July 3, 2025 | cen.acs.orgC

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 3, 2025 | globenewswire.com

Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions

June 12, 2025 | bioworld.comB

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

June 10, 2025 | globenewswire.com

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Roche strikes Orionis deal to develop ‘molecular glues’ for cancer

May 21, 2025 | biopharmadive.comB

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

May 8, 2025 | zacks.com

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

May 8, 2025 | globenewswire.com

Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 6.04%

May 6, 2025 | aaii.comA

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

April 28, 2025 | globenewswire.com

Monte Rosa Therapeutics Insider Ups Holding During Year

April 22, 2025 | finance.yahoo.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in Stock

March 26, 2025 | insidertrades.com

Monte Rosa Therapeutics: Exercise Extreme Caution

March 25, 2025 | seekingalpha.com

Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush

March 23, 2025 | markets.businessinsider.com

Monte Rosa Therapeutics price target lowered to $10 from $11 at Wells Fargo

March 22, 2025 | markets.businessinsider.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript

March 22, 2025 | msn.com

Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)

March 22, 2025 | markets.businessinsider.com

Wedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

March 22, 2025 | markets.businessinsider.com

Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 17.85%

March 21, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Buybacks Galore: Repurchases From the Oval Office to Olive Garden
By Leo Miller | June 30, 2025
View Buybacks Galore: Repurchases From the Oval Office to Olive Garden
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market
Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
By Thomas Hughes | June 23, 2025
View Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback

ELUT, FULC, AURA, and GLUE Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.78 -0.35 (-4.85%)

As of 03:36 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Elutia NASDAQ:ELUT

$2.11 +0.08 (+3.94%)

As of 03:35 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Fulcrum Therapeutics NASDAQ:FULC

$7.66 -0.28 (-3.46%)

As of 03:35 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$5.88 -0.02 (-0.25%)

As of 03:35 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time